PE20011164A1 - Derivados de eteres de pirazol como agentes antiinflamatorios / analgesicos - Google Patents
Derivados de eteres de pirazol como agentes antiinflamatorios / analgesicosInfo
- Publication number
- PE20011164A1 PE20011164A1 PE2001000213A PE2001000213A PE20011164A1 PE 20011164 A1 PE20011164 A1 PE 20011164A1 PE 2001000213 A PE2001000213 A PE 2001000213A PE 2001000213 A PE2001000213 A PE 2001000213A PE 20011164 A1 PE20011164 A1 PE 20011164A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halogen
- pirazole
- inflammatory
- ethers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
Abstract
SE REFIERE DERIVADOS A ETER,TIOETER, AMINA DE PIRAZOL DE FORMULA I DONDE A ES O, S, SO, SO2, NR4; X ES CR7, N; Y ES CR8, N; R1 ES ALQUILO C1-C6, NH2; R2 ES H, HALOGENO, HIDROXI, MERCAPTO, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R3 ES ALQUILO C1-C6, ARILO C6-C10, CICLOALQUILO C3-C10, HETEROARILO, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, ALQUILSULFONILO C1-C6, ALQUILO C1-C6-C=O, ENTRE OTROS; R5 ES H, HALOGENO, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R6 ES H, HALOGENO, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R7 ES H, HALOGENO, OH, MERCAPTO, ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS; R8 ES H, HALOGENO, OH, MERCAPTO, ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS; SON COMPUESTOS PREFERIDOS 2-(5-ISOBUTOXI-3-TRIFLUOROMETILPIRAZOL-1-IL]-5-METANOSULFONILPIRIDINA; 2-[5-(1-ETILPROPOXI)-3-TRIFLUOROMETILPIRAZOL-1-IL]-5-METANOSULFONILPIRIDINA, ENTRE OTROS; LOS COMPUESTOS I INHIBEN LA BIOSINTESIS DE PROSTAGLANDINAS Y PUEDEN SER UTILES PARA TRATAR ARTRITIS, FIEBRE, RESFRIO, DISMENORREA, CALAMBRES MESTRUALES, NEURODEGENERACION, CANCER DE COLON
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18686900P | 2000-03-03 | 2000-03-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20011164A1 true PE20011164A1 (es) | 2001-11-13 |
Family
ID=22686598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000213A PE20011164A1 (es) | 2000-03-03 | 2001-03-01 | Derivados de eteres de pirazol como agentes antiinflamatorios / analgesicos |
Country Status (16)
Country | Link |
---|---|
US (3) | US6878726B2 (es) |
EP (1) | EP1259504A1 (es) |
JP (1) | JP2003525288A (es) |
AR (1) | AR027967A1 (es) |
AU (2) | AU2001232175B2 (es) |
BR (1) | BR0108908A (es) |
CA (1) | CA2401697A1 (es) |
CO (1) | CO5271651A1 (es) |
GT (1) | GT200100036A (es) |
HN (1) | HN2001000037A (es) |
MX (1) | MXPA02008627A (es) |
PA (1) | PA8513101A1 (es) |
PE (1) | PE20011164A1 (es) |
TN (1) | TNSN01035A1 (es) |
WO (1) | WO2001064669A1 (es) |
ZA (1) | ZA200207015B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2401697A1 (en) * | 2000-03-03 | 2001-09-07 | Pfizer Products Inc. | Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
US20040092552A1 (en) * | 2000-04-25 | 2004-05-13 | Brown David L | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation |
PT1441714E (pt) * | 2001-10-25 | 2008-03-10 | Novartis Ag | Combinações compreendendo um inibidor selectivo da ciclo-oxigenase 2 |
WO2003037352A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders |
WO2003037330A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors |
EP1440062A1 (en) | 2001-11-02 | 2004-07-28 | Pfizer Products Inc. | An efficient synthesis of 5-heteroatom-containing-pyrazoles |
WO2003037336A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer |
WO2003037351A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors |
WO2003037335A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 5-heteroatom-substituted pyrazoles |
AU2003258630A1 (en) * | 2002-08-19 | 2004-03-11 | Glaxo Group Limited | Pyrimidine derivatives as selective cox-2 inhibitors |
CA2549017A1 (en) | 2003-08-01 | 2005-02-10 | Mona Patel | Substituted indazole-o-glucosides |
CA2549015A1 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted fused heterocyclic c-glycosides |
US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
CA2549022A1 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides |
BRPI0413232B8 (pt) | 2003-08-01 | 2021-05-25 | Mitsubishi Tanabe Pharma Corp | composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto |
UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
JP5596545B2 (ja) | 2007-09-10 | 2014-09-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Sgltの阻害物質として有用な化合物の製造方法 |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
DE112010001898T5 (de) | 2009-04-27 | 2012-08-02 | Dow Agrosciences Llc | Insektizide Pyridinverbindungen |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
US9174971B2 (en) | 2009-10-14 | 2015-11-03 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
KR101931209B1 (ko) | 2010-05-11 | 2018-12-20 | 얀센 파마슈티카 엔.브이. | Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형 |
AU2012241897C1 (en) | 2011-04-13 | 2017-05-11 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of SGLT2 |
TWI542596B (zh) | 2011-05-09 | 2016-07-21 | 健生藥品公司 | (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體 |
CA2867467A1 (en) | 2012-03-16 | 2013-09-19 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
SG11201705088VA (en) | 2014-12-23 | 2017-07-28 | Axikin Pharmaceuticals Inc | 3,5-diaminopyrazole kinase inhibitors |
CN104892514A (zh) * | 2015-05-19 | 2015-09-09 | 广州诺威生物技术有限公司 | 一种咪唑类新化合物 |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3575130D1 (de) * | 1984-05-12 | 1990-02-08 | Fisons Plc | Antiinflammatorische 1,n-diarylpyrazol-3-amine, deren zusammensetzungen und verfahren zu deren herstellung. |
FI855180A (fi) * | 1985-01-18 | 1986-07-19 | Nissan Chemical Ind Ltd | Pyrazolsulfonamidderivat, foerfarande foer dess framstaellande och det innehaollande ograesgift. |
US4881985A (en) * | 1988-08-05 | 1989-11-21 | General Motors Corporation | Method for producing anisotropic RE-FE-B type magnetically aligned material |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
FR2652352A1 (fr) | 1989-09-28 | 1991-03-29 | Jouveinal Sa | Benzodiazepines, leur procede et intermediaires de preparation et leurs applications en therapeutique. |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5434178A (en) * | 1993-11-30 | 1995-07-18 | G.D. Searle & Co. | 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation |
FR2725719B1 (fr) | 1994-10-14 | 1996-12-06 | Jouveinal Inst Rech | Diazepino-indoles inhibiteurs de phosphodiesterases iv |
US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
FR2746800B1 (fr) | 1996-03-29 | 1998-06-05 | Jouveinal Inst Rech | Diazepino-indoles inhibiteurs de phosphodiesterases 4 |
EP0892791B1 (en) * | 1996-04-12 | 2003-03-05 | G.D. Searle & Co. | N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS |
FR2762841B1 (fr) | 1997-04-30 | 1999-07-02 | Jouveinal Inst Rech | Diazepino-indolones inhibitrices de phosphodiesterases iv |
WO1999015513A1 (en) | 1997-09-24 | 1999-04-01 | Merck & Co., Inc. | Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of cox-2 |
JP2001521932A (ja) | 1997-10-30 | 2001-11-13 | メルク フロスト カナダ アンド カンパニー | 選択的シクロオキシゲナーゼ−2−阻害剤としてのジアリール−5−アルキル−5−メチル−2(5h)−フラノン |
CN1147476C (zh) * | 1998-05-05 | 2004-04-28 | 霍夫曼-拉罗奇有限公司 | 作为p-38map激酶抑制剂的吡唑衍生物 |
JP2000169453A (ja) * | 1998-09-30 | 2000-06-20 | Mitsubishi Chemicals Corp | 1―フェニルピラゾ―ル―3―カルボキサミド誘導体、その中間体およびこれを有効成分とする農薬 |
CA2401697A1 (en) * | 2000-03-03 | 2001-09-07 | Pfizer Products Inc. | Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
-
2001
- 2001-02-22 CA CA002401697A patent/CA2401697A1/en not_active Abandoned
- 2001-02-22 AU AU2001232175A patent/AU2001232175B2/en not_active Ceased
- 2001-02-22 MX MXPA02008627A patent/MXPA02008627A/es unknown
- 2001-02-22 JP JP2001563509A patent/JP2003525288A/ja active Pending
- 2001-02-22 BR BR0108908-0A patent/BR0108908A/pt not_active IP Right Cessation
- 2001-02-22 WO PCT/IB2001/000237 patent/WO2001064669A1/en not_active Application Discontinuation
- 2001-02-22 EP EP01904263A patent/EP1259504A1/en not_active Withdrawn
- 2001-02-22 AU AU3217501A patent/AU3217501A/xx active Pending
- 2001-03-01 AR ARP010100978A patent/AR027967A1/es not_active Application Discontinuation
- 2001-03-01 PE PE2001000213A patent/PE20011164A1/es not_active Application Discontinuation
- 2001-03-02 TN TNTNSN01035A patent/TNSN01035A1/fr unknown
- 2001-03-02 US US09/798,752 patent/US6878726B2/en not_active Expired - Fee Related
- 2001-03-02 GT GT200100036A patent/GT200100036A/es unknown
- 2001-03-02 HN HN2001000037A patent/HN2001000037A/es unknown
- 2001-03-02 CO CO01016923A patent/CO5271651A1/es not_active Application Discontinuation
- 2001-03-02 PA PA20018513101A patent/PA8513101A1/es unknown
-
2002
- 2002-09-02 ZA ZA200207015A patent/ZA200207015B/en unknown
-
2004
- 2004-07-16 US US10/893,521 patent/US20050004135A1/en not_active Abandoned
- 2004-07-16 US US10/893,520 patent/US20040259879A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HN2001000037A (es) | 2001-06-18 |
CA2401697A1 (en) | 2001-09-07 |
AR027967A1 (es) | 2003-04-16 |
WO2001064669A1 (en) | 2001-09-07 |
JP2003525288A (ja) | 2003-08-26 |
BR0108908A (pt) | 2002-12-24 |
EP1259504A1 (en) | 2002-11-27 |
AU2001232175B2 (en) | 2005-07-07 |
US6878726B2 (en) | 2005-04-12 |
TNSN01035A1 (fr) | 2005-11-10 |
AU3217501A (en) | 2001-09-12 |
CO5271651A1 (es) | 2003-04-30 |
US20050004135A1 (en) | 2005-01-06 |
US20020058681A1 (en) | 2002-05-16 |
MXPA02008627A (es) | 2003-02-24 |
PA8513101A1 (es) | 2003-06-30 |
GT200100036A (es) | 2001-12-18 |
US20040259879A1 (en) | 2004-12-23 |
ZA200207015B (en) | 2003-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20011164A1 (es) | Derivados de eteres de pirazol como agentes antiinflamatorios / analgesicos | |
PE20160654A1 (es) | Compuestos de inhibidor de autotaxina | |
HRP20090162T1 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
ECSP055594A (es) | Nuevos derivados de 2-piridiletilbenzamida | |
CO4960662A1 (es) | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados | |
RS39604A (en) | Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators | |
DE60204674D1 (de) | Retinoid x rezeptormodulatoren | |
CO5540309A2 (es) | Derivados de 4-(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor, la ansiedad o desordenes gastrointestinales | |
RS50437B (sr) | Benzoilpirazoli i njihova primena u ulozi herbicida | |
CY1113648T1 (el) | Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης | |
PT1167355E (pt) | Forma cristalina de celecoxib | |
PE20020957A1 (es) | Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas | |
RS50672B (sr) | Postupak za pripremanje n-fenilpirazol-1-karboksamida | |
AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
AR054130A1 (es) | Procedimiento para la preparacion de 1-alquil-3-feniluracilos | |
NO20010991D0 (no) | Pyrro-indoler, pyrido-indoler og azepino-indoler som 5-HT2C- agonister | |
PE20050131A1 (es) | Derivados de benzoimidazol como agentes antiproliferativos | |
MY136685A (en) | Thiazole derivatives for treating ppar related disorders | |
WO2007149448A3 (en) | Pyrazinones as cellular proliferation inhibitors | |
DK1047690T3 (da) | Heterocykliske ether- og thioetherforbindelser, som er anvendelige til regulering af kemisk, synaptisk overförsel | |
UY29070A1 (es) | Enantiómeros de heterocíclicos fusionados y sus usos | |
PE20030208A1 (es) | Derivados de indirubina que contienen azufre, su preparacion y uso | |
AR060813A1 (es) | Moduladores de mglur5 iii | |
CO5560606A2 (es) | Hidratos cristalinos de derivados de anilida de acido nicotinico | |
PE20090703A1 (es) | Nuevo procedimiento de sintesis del ranelato de estroncio y de sus hidratos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |